Oocyte Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes. (WCFC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To document the freeze/thaw survival rates of human oocytes and to compare the structure changes in their meiotic spindle and mitochondria before and after cryopreservation. [ Time Frame: When study complete ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years to 37 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Women of reproductive age who undergo controlled ovarian hyperstimulation (COH) for IVF are recruited for this study.
To be eligible for inclusion into this study, each subject must satisfy the following criteria:
Participants must be aged 21 to 35 years
Body mass index (BMI) < 38.
Serum results for cycle day 3 FSH <10 mIU/ml.
Be willing and able to comply with the protocol for the duration of the study.
Have voluntarily provided written informed consent under WIRB, prior to any study-related procedure that is not part of normal medical care, with the understanding that the subjects may withdraw consent anytime without prejudice to their future medical care.
Have passed a psychological and physical screening.
A patient may NOT be entered into the study if she presents with ANY of the following criteria:
Clinically significant systemic disease.
Known endometriosis Grade III - IV (ASRM classification).
Any previous cycle indicating a low response to gonadotropin stimulation (defined as retrieval of < 10 eggs at retrieval)
Previous ovarian surgery
Known allergy or hypersensitivity to recombinant gonadotropin preparations or any other study-related medications.
Known current substance abuse.
Simultaneous participation in another clinical trial.
An extrauterine pregnancy within the last 3 months before OCP treatment commences.
Previous participation in similar study at different centers.